PACB
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
NASDAQ · Healthcare · Medical - Devices · US
$1.37
−0.72%Sep 17, 2026, 23:15 UTC
Pacific Biosciences of California (PACB) shares closed at $1.38, up 2.99% from the previous trading session.
Source:Sep 2, 2026, 18:56 UTC
PacBio cut its 2026 revenue outlook due to weaker instrument demand and a slower SPRQ-Nx transition.
Source:Aug 16, 2026, 07:02 UTC
Pacific Biosciences of California cut its outlook due to slower SPRQ-N transition and targeted cash-flow positivity by 2028.
Source:Aug 6, 2026, 04:04 UTC
Pacific Biosciences of California announced an immediate leadership transition.
Source:Aug 5, 2026, 20:05 UTC
PacBio announced its financial results for the quarter ended June 30, 2026, on August 5, 2026.
Jun 4, 2026, 00:00 UTC
Pacific Biosciences of California elected William Ericson, Kathy Ordoñez, Christopher M. Smith, Chris Gibson, and Christian O. Henry as Class III directors, effective June 3, 2026.
Jun 1, 2026, 16:11 UTC
PacBio (PACB) launched the commercial availability of SPRQ-Nx technology for its Revio sequencing system, which lowers sequencing costs by about 30% and adds AI and epigenetics upgrades.
Source: